ClinicalTrials.gg
TerminatedNCT00832572Updated Jun 30, 2014Results posted

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

A Phase 4 interventional study of Ranolazine and Placebo in Coronary Artery Disease, Pain and Peripheral Nervous System Diseases, sponsored by Gilead Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-30.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ranolazine in Coronary Artery Disease — none open to participants now, none under way, none of them phase 3. Ranolazine · Coronary Artery Disease.

Enrollment
13th of 15
5 · median 50
Started
2009
the only one that year
Phase 4
8 of 15
none open now
Registered
2nd of 15
by date
Lead sponsor
6 of 15
Gilead Sciences

Among the 15 studies testing ranolazine in Coronary Artery Disease, this one is the 13th largest by enrollment, is the only one that started in 2009, is one of 8 in phase 4, and was the 2nd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

None of the 15 studies testing ranolazine in Coronary Artery Disease is open now. The open studies under Coronary Artery Disease, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing ranolazine in Coronary Artery Disease as a file.
02

Study summary

This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease.

Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.

03

Conditions studied

  • Coronary Artery Disease
  • Pain
  • Peripheral Nervous System Diseases
  • Polyneuropathy

Keywords

  • Coronary Artery Disease
  • Pain
  • Peripheral Neuropathy
  • Polyneuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged ≥ 18 years
  • Coronary artery disease with a clinically diagnosed peripheral neuropathy
  • Willing and able to provide signed and Health Insurance Portability and Accountability Act (HIPAA) authorization
  • Willing and able to comply with the requirements of the protocol and follow directions from the clinic staff

Exclusion criteria

Exclusion Criteria:

  • History of allergy or intolerance to ranolazine
  • Any condition or concomitant medication that would have precluded the safe use of ranolazine as outlined in the prescribing information sheet (see Appendix E)
  • In the judgment of the investigator, any clinically-significant ongoing medical condition that might jeopardize the patient's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug
  • In the judgment of the investigator, clinically-significant abnormal physical findings during screening (excluding the patient's peripheral neuropathy condition)
  • Use of any experimental or drug or device within 30 days prior to screening
  • Pregnant or breast feeding, or (if premenopausal), not practicing an acceptable method of (as detailed in Inclusion Criterion 4)
  • Had received prior treatment with, or investigational exposure to, ranolazine within 7 days prior to randomization
  • hepatic impairment
  • Had end-stage renal disease requiring dialysis
  • Psychological or addictive disorders (not limited to, but including drug and/or alcohol dependency) that may have precluded patient consent or compliance, or that may have confounded study interpretation
  • Positive pregnancy test at Baseline (pre-randomization, Day 0)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Placebo-Ranolazine

    Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.

    Drug: Ranolazine · Drug: Placebo

  • Experimental
    Ranolazine-Placebo

    Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.

    Drug: Ranolazine · Drug: Placebo

Interventions

  • Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).

    Also known as: Ranexa

  • DrugPlacebo

    Placebo to match ranolazine administered twice a day for 6 weeks

06

What researchers measure

Primary outcomes

  1. Reduction in Neuropathic Pain

    Reduction in patient-reported neuropathic pain (by 2 numeric levels as measured by the Numeric Pain Scale)

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Assess Participant Quality of Life Utilizing the Short Form 36 Health Survey (SF-36v2) Questionnaire

    The participant quality of life assessed utilizing the SF-36v2 questionnaire

    Time frame: Baseline to Week 6

  2. Response to Thermal and Mechanical Stimuli

    The participant response to thermal and mechanical stimuli as measured by the Hargreaves and Von Frey tests

    Time frame: Baseline to Week 6

07

Results

Posted Jun 30, 2014
Limitations and caveats
The study was stopped after 5 participants were enrolled. No outcome measure analyses were performed. Adverse events were collected and reported to the study center's Institutional Review Board.

Participant flow

Five participants were enrolled and treated.

Period 1
Participant flow — Period 1
MilestonePlacebo/RanolazineRanolazine/Placebo
Started32
Completed32
Not completed00
Period 2
Participant flow — Period 2
MilestonePlacebo/RanolazineRanolazine/Placebo
Started32
Completed32
Not completed00

Outcome measures

PrimaryReduction in Neuropathic Pain

Reduction in patient-reported neuropathic pain (by 2 numeric levels as measured by the Numeric Pain Scale)

Time frame:
Baseline to Week 6

No measurements were reported for this outcome.

SecondaryAssess Participant Quality of Life Utilizing the Short Form 36 Health Survey (SF-36v2) Questionnaire

The participant quality of life assessed utilizing the SF-36v2 questionnaire

Time frame:
Baseline to Week 6

No measurements were reported for this outcome.

SecondaryResponse to Thermal and Mechanical Stimuli

The participant response to thermal and mechanical stimuli as measured by the Hargreaves and Von Frey tests

Time frame:
Baseline to Week 6

No measurements were reported for this outcome.

Adverse events

Collected over Up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Ranolazine, Period 1—0/3 (0%)1/3 (33.3%)
Placebo/Ranolazine, Period 2—0/3 (0%)0/3 (0%)
Ranolazine/Placebo, Period 1—0/2 (0%)0/2 (0%)
Ranolazine/Placebo, Period 2—0/2 (0%)1/2 (50%)
Most frequent other events
Most frequent other events
EventPlacebo/Ranolazine, Period 1Placebo/Ranolazine, Period 2Ranolazine/Placebo, Period 1Ranolazine/Placebo, Period 2
FeverGeneral disorders0/30/30/21/2
ChillsGeneral disorders0/30/30/21/2
HeadacheNervous system disorders0/30/30/21/2
Sensitivity to light (eyes)Nervous system disorders0/30/30/21/2
Right leg muscle tendon pulledMusculoskeletal and connective tissue disorders0/30/30/21/2
Stabbing pain to right leg calfMusculoskeletal and connective tissue disorders0/30/30/21/2
Aching pain to right calfMusculoskeletal and connective tissue disorders0/30/30/21/2
Expiratory wheezingMusculoskeletal and connective tissue disorders1/30/30/20/2

Baseline characteristics

All enrolled and treated participants

Age, Categorical
Age, Categorical(Participants)Placebo/RanolazineRanolazine/PlaceboTotal
<=18 years000
Between 18 and 65 years022
>=65 years303
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/RanolazineRanolazine/PlaceboTotal
Female112
Male213
08

Study locations

1 site
  • Cardiovascular Institute of the South Clinical Research Corporation
    Houma, Louisiana 70360, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2009
First posted
Jan 30, 2009
Start
Jan 2009
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Jun 30, 2014
Last update
Jun 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00832572
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 30, 2009
Start date
Jan 2009
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jun 30, 2014
Last update
Jun 30, 2014

Study contacts

Craig Walker, MD
principal investigator · Cardiovascular Institute of the South Clinical Research Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion